“The results of this survey told us what companies within the drug development services industry are currently doing and identified areas for improvement,” said Cinda Orr, SCORR Marketing president and chief executive officer. “Marketing is an expense, and it requires accountability and measurable results to be considered a company asset.”
“We also found that companies are not measuring the results of their marketing efforts,” said Ms. Orr. “How are you going to meet your business goals if you do not have a plan to get there? How are you going to know what is working and not working if you do not measure the results? These companies are also putting themselves at risk because the wrong message could damage their company,” added Ms. Orr.
The full report is available at scorrmarketing.com